[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

La Merie Publishing: Market Research Reports

Set up in 2002, La Merie Publishing is an authoritative supplier of the cutting-edge information on the biopharmaceutical industry, with a special focus on the research and development pipeline and covering issues related to biologics, including peptides, antibodies, DNA, RNA, proteins and cell therapy.

The company’s service portfolio is represented by various formats and price levels, and includes Brief Reports, Full Reports and Competitor Analysis Reports. Competitor Analysis Reports present no frills, but accurate data on the pipeline of research and development projects for diseases, targets, companies and technologies. The data are fully referenced and delivered in a tabular format. Brief Reports covering Target Pipelines contain all-round assessments of both business and scientific perspectives of new targets. Full Reports present deep analyses of product portfolios, competitive landscape, R&D pipelines and discussions of the pipeline perspectives.

Publications found: 221
Sort by:
Competitor Analysis: KRAS Inhibitors US$ 238.00

Competitor Analysis: KRAS Inhibitors This Competitive Intelligence report about KRAS Inhibitors evaluates the landscape of investigational small molecules, antibodies, cell therapeutics and vaccines t...

October 2019 35 pages
RNA-Targeted Small Molecules 2019: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective US$ 1,998.00

RNA-Targeted Small Molecules 2019: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective This report provides ...

September 2019 223 pages
Competitor Analysis: RORgamma Antagonists and Agonists US$ 238.00

Competitor Analysis: RORgamma Antagonists and Agonists This Competitive Intelligence report about RORgamma Antagonists and Agonists evaluates the landscape of investigational small molecules targeting...

September 2019 28 pages
Competitor Analysis: TGF-beta/Receptor Inhibitors US$ 289.00

Competitor Analysis: TGF-beta/Receptor Inhibitors This Competitive Intelligence report about TGF-beta/Receptor Inhibitors evaluates the landscape of investigational new molecular entities targeting tr...

September 2019 59 pages
Report Package: Bispecific Antibodies US$ 2,840.00

Report Package: Bispecific Antibodies This report package includes the full report T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a business, stakeholder, technology and pipeline analysis and the ...

June 2019
T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a Business, Stakeholder, Technology and Pipeline Analysis US$ 2,295.00

... of 38 established or emerging T-cell or NK-cell engaging antibody technologies; Profiles of one approved, 89 T-cell or NK-cell engaging bispecific antibodies in all phases of development, and analysis of eight discontinued bispecific T-cell engagers; Technology selection and ...

June 2019 463 pages
Competitor Analysis: Bispecific Antibodies for Immuno-Oncology & Other Diseases US$ 765.00

Competitor Analysis: Bispecific Antibodies for Immuno-Oncology & Other Diseases This Competitive Intelligence report about Bispecific Antibodies for Immuno-Oncology & Other Diseases evaluates the landscape of investigational ...

June 2019 121 pages
Competitor Analysis: CD40, GITR, OX40, 4-1BB, CD27, ICOS & Other Immune Checkpoint Activators 2018 US$ 502.00

Competitor Analysis: CD40, GITR, OX40, 4-1BB, CD27, ICOS & Other Immune Checkpoint Activators 2018 This Competitive Intelligence report analyzes the competitive field of CD40, GITR, OX40, 4-1BB, CD27, ICOS ...

July 2018 78 pages
Competitor Analysis: Tumor Microenvironment Modulation via IDO, TGF-?, CXCR4, CSF-1R, CD47-SIRP?, adenosine pathway & STING 2018 US$ 799.00

Competitor Analysis: Tumor Microenvironment Modulation via IDO, TGF-β, CXCR4, CSF-1R, CD47-SIRPα, adenosine pathway ... . In addition, the report lists company-specific R&D pipelines of modulators of the tumor microenvironment. Competitor projects are listed in a tabular format providing information on: Drug ...

July 2018 204 pages
Report Package Immuno-Oncology: Inhibitory and Stimulatory Immunomodulators US$ 1,437.00

Report Package Immuno-Oncology: Inhibitory and Stimulatory Immunomodulators This product consists of four reports in pdf ... include compilations of currently active projects in research and development of immunomodulators in immuno-oncology. In addition, each report lists company-specific R&D pipelines of ...

July 2018 455 pages
Competitor Analysis: PD-1 and PD-L1 Immune Checkpoint Inhibitors 2018 US$ 604.00

Competitor Analysis: PD-1 and PD-L1 ... specific R&D pipelines of PD-1 and PD-L1 checkpoint inhibitors. Competitor projects are listed in a tabular format providing information ... to the source of information. About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information ...

June 2018 89 pages
Competitor Analysis: PRAME-Targeted Immunotherapy US$ 150.00

Competitor Analysis: PRAME-Targeted Immunotherapy This Competitive Intelligence report analyzes the competitive field of PRAME-Targeted Immunotherapies as of June 2018 in a tabulated format with structured listings of industry-relevant data. PRAME (preferentially ...

June 2018 23 pages
Competitor Analysis: WT1-Targeted Immunotherapy US$ 301.00

Competitor Analysis: WT1-Targeted Immunotherapy This Competitive Intelligence report analyzes the competitive field of WT1-Targeted Immunotherapies as of June 2018 in a tabulated format with structured listings of industry-relevant ...

June 2018 52 pages
Competitor Analysis: hTERT-Targeted Immunotherapy US$ 150.00

Competitor Analysis: hTERT-Targeted Immunotherapy This Competitive Intelligence report analyzes the competitive field of hTERT-Targeted Immunotherapies as of June 2018 in a tabulated format with structured listings of industry-relevant ...

June 2018 20 pages
Competitor Analysis: NY-ESO-1-Targeted Immunotherapy US$ 401.00

Competitor Analysis: NY-ESO-1-Targeted Immunotherapy This Competitive Intelligence report analyzes the competitive field of NY-ESO-1-Targeted Immunotherapies as of June 2018 in a tabulated format with structured listings of industry-relevant ...

June 2018 72 pages
Competitor Analysis: MAGE-A-Targeted Immunotherapy US$ 150.00

Competitor Analysis: MAGE-A-Targeted Immunotherapy This Competitive Intelligence report analyzes the competitive field of MAGE-A-Targeted Immunotherapies as of June 2018 in a tabulated format with structured listings of industry-relevant ...

June 2018 28 pages
Report Package: Immunotherapeutics Targeting MAGE-A, NY-ESO-1, hTERT, WT1, PRAME and Survivin US$ 812.00

Report Package: Immunotherapeutics Targeting MAGE-A, NY-ESO-1, hTERT, WT1, PRAME and Survivin Intracellular cancer targets are estimated to be 3-4 times more frequent than surface protein targets. However, these ...

June 2018 223 pages
Competitor Analysis: CTLA-4, LAG-3, TIM-3, TIGIT & Other Immune Checkpoint Inhibitors 2018 US$ 502.00

Competitor Analysis: CTLA-4, LAG-3, TIM-3, TIGIT & Other Immune Checkpoint Inhibitors 2018 This Competitive Intelligence report analyzes the competitive field of CTLA-4, LAG-3, TIM-3, TIGIT & Other Immune Checkpoint Inhibitors ...

June 2018 84 pages
TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals US$ 2,157.00

... less successful against solid tumors. This report „TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & ... acquisition prices and financing rounds. Download Sample Pages: TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders ...

May 2018 294 pages
Competitor Analysis: Survivin-Targeted Immunotherapy US$ 201.00

Competitor Analysis: Survivin-Targeted Immunotherapy This Competitive Intelligence report analyzes the competitive field of Survivin-Targeted Immunotherapies as of May 2018 in a tabulated format with structured listings of industry-relevant ...

May 2018 28 pages
Report Package: TCR-Based Antibody and T-Cell Immunotherapy US$ 3,505.00

T-Cell Receptor (TCR)-based therapeutic cells and recombinant antibodies or antibody fusion proteins have emerged as a new class of ... or T-cell redirecting bispecific antibodies. This report package includes two full reports covering TCR-based T-cell and recombinant antibody (fusion protein) immunotherapy ...

April 2018
Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trends US$ 2,380.00

... that there are 3-4 times more intracellular targets than surface protein targets. However, these intracellular cancer targets are not accessible to traditional monoclonal ... p53 or Ras, β-catenin and Myc. This report „Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell- ...

January 2018 252 pages
Competitor Analysis: Anti-VEGF and Anti-VEGF-R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis – a 2017 Update US$ 446.00

Competitor Analysis: Anti-VEGF and Anti-VEGF-R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis – a 2017 Update The Competitive Intelligence Report „Anti-VEGF & Anti-VEGF-R Biosimilars and Biosuperiors of Avastin ...

November 2017 58 pages
Report Package: Immunotherapy with Oncolytic Viruses and mRNA Vaccines & Therapeutics US$ 3,060.00

Report Package: Immunotherapy with Oncolytic Viruses and mRNA Vaccines & Therapeutics mRNA is a rather versatile therapeutic ... as a cancer vaccine. The so far modest efficacy of oncolytic viruses still can be improved when combined with immune checkpoint inhibitors. This lead to an increased ...

October 2017
Flat-Rate Subscription to La Merie Publishing Reports & News Services US$ 5,015.00

... ; R&D Pipeline News - Therapeutic Area Edition. After purchase of the Flat-Rate Subscription to La Merie Publishing Reports & News Services , credentials to access a dedicated server ...

October 2017
Competitor Analysis: Mesothelin-Targeted Antibodies, Vaccines & T-Cells 2017 US$ 298.00

... report about Mesothelin-Targeted Antibodies, Vaccines & T-Cells 2017 provides a competitor evaluation in the field of antibodies, vaccines and engineered chimeric antigen receptor (CAR) T-cells targeting mesothelin as of August 2017. Mesothelin is a surface ...

August 2017 29 pages
mRNA Vaccines & Therapeutics 2017: an industry analysis of technologies, pipelines, stakeholders and deals US$ 2,142.00

... mRNA Vaccines & Therapeutics 2017: an industry analysis of technologies, pipelines, stakeholders and deals as of June 2017 brings you up-to-date regarding key mRNA players, key mRNA technologies and applications, mRNA vaccines & therapeutics ...

June 2017 260 pages
Competitor Analysis: Kallikrein Inhibitors 2017 US$ 145.00

Competitor Analysis: Kallikrein Inhibitors & Bradykinin Receptor Antagonists The present Competitive Intelligence report aboutKallikrein Inhibitors & Bradykinin Receptor Antagonists provides a competitor evaluation in the field of marketed and novel ...

April 2017 17 pages
Competitor Analysis: Respiratory Syncytial Virus (RSV) Antibodies, Vaccines & Antivirals 2017 US$ 383.00

Competitor Analysis: Respiratory Syncytial Virus (RSV) Antibodies, Vaccines & Antivirals 2017 This Competitive Intelligence Report about RSV Antibodies, Vaccines & Antivirals provides a competitor evaluation in the field of prophylactic ...

March 2017 53 pages
Blockbuster Biologics 2016: Sales of Recombinant Therapeutic Antibodies & Proteins US$ 136.00

Blockbuster Biologics 2016: Sales of Recombinant Therapeutic Antibodies & Proteins This report prepared by La Merie Publishing provides a compilation of the sales data of originator recombinant therapeutic proteins and antibodies ...

March 2017 45 pages
Competitor Analysis: Complement C5 Inhibitors 2017 - Biosuperiors & Biosimilars US$ 196.00

Competitor Analysis: Complement C5 Inhibitors 2017 Biosuperiors & Biosimilars This Competitive Intelligence report about Complement C5 Inhibitors 2017 Biosuperiors & Biosimilars provides a competitor evaluation in the field of mainly recombinant antibodies, but ...

March 2017 21 pages
The Oncolytic Virus Landscape 2017: an Analysis of Pipeline, Stakeholders, Deals, Industry Trends & Opportunities US$ 2,040.00

The Oncolytic Virus Landscape 2017: an analysis of pipeline, stakeholders, deals, industry trends & opportunities The field of oncolytic viruses was quite dormant in the first decade of the 2000s ... „The Oncolytic Virus Landscape 2017: an analysis of pipeline, stakeholders, deals, industry trends & opportunities“ as of January 2017 brings you up-to-date regarding key players, key technologies, Oncolytic Virus projects ...

January 2017 225 pages
Competitor Analysis: CSF-1R Antagonists for Modulation of the Tumor Microenvironment US$ 312.00

Competitor Analysis: CSF-1R Antagonists for Modulation of the Tumor Microenvironment This industry report describes the competitive R&D landscape of novel colony stimulating receptor 1 (CSF-1R) antagonists for modulation of the immunosuppressive tumor microenvironment as of December 2016. The Competitor Analysis includes antibody-based antagonists of CSF-1R as well as small molecule inhibitors of CSF-1R tyrosine ...

December 2016 19 pages
Competitor Analysis: CXCR4 Antagonists for Modulation of the Tumor Microenvironment US$ 312.00

Competitor Analysis: CXCR4 Antagonists for Modulation of the Tumor Microenvironment This industry report describes the competitive R&D landscape of novel antagonists of the C-X-C chemokine receptor type 4 (CXCR4) and ... 2016. The Competitor Analysis includes antagonists of CXCR4 based on small molecules, peptides and antibodies as well as inhibitors of CXCL12, the ligand for CXCR4. Included are molecules ...

December 2016 20 pages
Competitor Analysis: IDO & TDO Inhibitors for Modulation of the Tumor Microenvironment US$ 312.00

Competitor Analysis: IDO & TDO Inhibitors for Modulation of the Tumor Microenvironment This industry report describes the competitive R&D landscape of specific IDO and TDO inhibitors as well as dual ... comments with a hyperlink leading to the source of information. About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information about the ...

December 2016 38 pages
Competitor Analysis: Inhibitory and Stimulatory Immunomodulators in Immuno-Oncology US$ 1,964.00

Competitor Analysis: Inhibitory and Stimulatory Immunomodulators in Immuno-Oncology This product consists of four reports in pdf ... Competitor Analysis: Tumor Microenvironment Modulation via IDO, TGF-β/R, CXCR4, CSF-1R, CD47-SIRPα, Adenosine, STING & Others Targets of Immunomodulators are inhibitory as well as stimulatory immune ...

December 2016 319 pages
Competitor Analysis: TGF-? Inhibitors for Modulation of the Tumor Microenvironment US$ 312.00

Competitor Analysis: TGF-β Inhibitors for Modulation of the Tumor Microenvironment This industry report describes the competitive R&D landscape of specific TGF-beta inhibitors as well as TGF-beta receptor antagonists ... 2016. The Competitor Analysis includes antibody-based inhibitors of transforming growth factor beta (TGF-beta) or antagonists of TGF-beta receptors as well as small molecule inhibitors of TGF-beta receptor ...

December 2016 22 pages
Competitor Analysis: Tumor Microenvironment Modulation via IDO, TGF-?/R, CXCR4, CSF-1R, CD47-SIRP?, Adenosine, STING & Others US$ 1,091.00

Competitor Analysis: Tumor Microenvironment Modulation via IDO, TGF-β/R, CXCR4, CSF-1R, CD47-SIRPα, Adenosine, STING & Others This Competitive Intelligence report about Tumor Microenvironment Modulation via IDO, TGF ... active projects in research and development of modulators of the tumor microenvironment. In addition, the report lists company-specific R&D pipelines of Tumor Microenvironment Modulators. Competitor projects are listed in a tabular format ...

December 2016 117 pages
Report Package: Hot targets for empowered antibody and cell therapy technologies US$ 1,777.00

... Package: Hot targets for empowered antibody and cell therapy technologies This package contains three reports analyzing BCMA, CD123 and CD22 as versatile and hot targets ... package of the three reports provides a 40% discount on the regular prices: B-Cell Maturation Antigen (BCMA): hot target for emerging treatment modalities CD123: a paradigmatic target ...

December 2016 202 pages
Antibody-Drug Conjugate Pipeline Review by target, drug, phase and company US$ 748.00

Antibody-Drug Conjugate Pipeline Review by target, drug, phase and company The competitive intelligence report „Antibody-Drug Conjugate Pipeline Review by target, drug, phase and company“ evaluates and describes the competitive landscape of antibody-drug conjugates ... -specific R&D pipelines of ADCs. Competitor projects are listed in a tabular format providing information on: Drug Codes, Target/Mechanism of Action, Class of Compound (antibody, linker, payload ...

December 2016 288 pages
R&D Drug Pipeline Database: 1-Year Subscription US$ 5,610.00

... Drug Pipeline Database: 1-Year Subscription Subscription to La Merie Publishing's proprietary R&D Drug Pieline Database provides 24/7 online access to information about more than 21,000 project ... a 1-year online access to the data of the R&D Drug Pipeline Database. Credentials to access the database will be sent by e-mail within 24 hours after purchase. Benefits from the R&D Drug Pipeline Database ...

November 2016
Flat-Rate Access to R&D Database & Reports from La Merie Publishing US$ 7,200.00

Unbenanntes Dokument Flat-Rate Access to R&D Database & Reports from La Merie Publishing R&D Drug Pipeline Database: 1-Year Subscription Flat-Rate Subscription to La Merie Publishing Reports & News Services A one-year ... . Internet access is the only prerequisite for this service. Upon purchse of the Flat-Rate Access to R&D Database & Reports from La Merie Publishing, credentials to access the database and a dedicated ...

November 2016
Anti-CD22 Immunotherapeutics in: October 2016 R&D and Business Tracker for Antibody-Drug Conjugates US$ 191.00

Anti-CD22 Immunotherapeutics in: October 2016 R&D and Business Tracker for Antibody-Drug Conjugates This pdf ... Pipeline: Anti-CD22 Immunotherapeutics CD-22Targeted Immunotherapeutics include: Naked Antibodies & Combinations Radioimmunotherapeutics Immunotoxins Antibody-Drug Conjugates Autologous CAR T-Cells Information about the anti-CD22 Immunotherapeutics pipeline ...

November 2016 27 pages
BCMA-Targeted Antibodies & T-Cells in: October 2016 R&D and Business Tracker for TCR & CAR T-Cells and NK Cells US$ 191.00

... : BCMA-Targeted Antibodies & T-Cellls BCMA-Targeted Antibodies & T-Cells include: Autologous & allogeneic T-Cells Bispecific tumor-targeted antibodies & T-cells Bispecific T-Cell and NK-Cell redirecting antibodies Antibody-Drug Conjugates Information about the BCMA-Targeted Antibodies & T-Cells pipeline ...

November 2016 27 pages
BCMA-Targeted Immunotherapeutics in: October 2016 R&D and Business Tracker for Bispecific Antibodies US$ 191.00

BCMA-Targeted Immunotherapeutics in: October 2016 R&D and Business Tracker for Bispecific Antibodies This pdf report contains information about Bispecific Antibodies released during the month of October 2016 ... Tracker for Bispecific Antibodies. Featured presentations of October 2016 include the pipeline of B-Cell Maturation Antigen (BCMA)-targeted immunotherapeutics, the profile of German technology company Pieris ...

November 2016 21 pages
CD22: a suitable antigen for targeted payload delivery by immunotherapeutics US$ 666.00

CD22: a suitable antigen for targeted payload delivery by immunotherapeutics This report describes and evaluates the competitive landscape of CD22-targeted immunotherapeutics based on different treatment ... , CD22 is rapidly internalized after binding of the anti-CD22 antibody and is not shed in the extracellular environment, features that make it an attractive antigen for ...

November 2016 80 pages
Competitor Analysis: Activators of Immune Checkpoints CD40, GITR, OX40, 4-1BB, CD27 & ICOS US$ 476.00

Competitor Analysis: Activators of Immune Checkpoints CD40, GITR, OX40, 4-1BB, CD27 & ICOS This Competitive Intelligence report about Activators of Immune Checkpoints CD40, GITR, OX40, 4-1BB, CD27 & ICOS provides a competitor evaluation as of November 2016 in the field of antibodies, proteins and vaccines stimulating immune ...

November 2016 75 pages
Competitor Analysis: Inhibitors of Negative Immune Checkpoints CTLA-4, LAG-3, TIM-3 & Others US$ 779.00

Competitor Analysis: Inhibitors of Negative Immune Checkpoints CTLA-4, LAG-3, TIM-3 & Others This Competitive Intelligence report about Inhibitors of Negative Immune Checkpoints CTLA-4, LAG-3, TIM-3 & Others evaluates ... comments with a hyperlink leading to the source of information. About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information about the ...

November 2016 74 pages
Anti-Her2 Antibody-Drug Conjugates in: September 2016 R&D and Business Tracker for Antibody-Drug Conjugates US$ 191.00

Anti-Her2 Antibody-Drug Conjugates in: September 2016 R&D and Business Tracker for Antibody-Drug Conjugates This pdf report contains information about Antibody-Drug Conjugates (ADCs) released during the month of September 2016. This ... for Antibody-Drug Conjugates. Featured presentations of September 2016 include the pipeline of Her2-targeted antibody-drug conjugates, the profile of Swiss biotech NBE Therapeutics and the profile of anti-Her2 antibody-drug conjugate MEDI4276 ...

October 2016 22 pages
CD123-Targeted Immunotherapeutics in: September 2016 R&D and Business Tracker for Bispecific Antibodies US$ 191.00

CD123-Targeted Immunotherapeutics in: September 2016 R&D and Business Tracker for Bispecific Antibodies This pdf report contains information about Bispecific Antibodies released during the month of September 2016. This issue forms part of the subscription service R&D and Business Tracker for Bispecific Antibodies. Featured presentations of September 2016 include the pipeline of CD123-targeted immunotherapeutics ...

October 2016 20 pages

Filters

Search

Categories

2
1
1
4
1
18
27
3
2
1
10
4
21
5
5
99
17

Publishers

221

Regions

221

Price

Date

Pages

Offers

1
4